UCB Q3 in line as Keppra holds
This article was originally published in Scrip
Executive Summary
In its interim report for the second half of the year, Belgium's UCB said its third quarter was in line with expectations, with revenue declining as a consequence to generic Keppra (levetiracetam) competition in the US. However, this was partially off-set by the strong performance of Keppra in Europe, which continued to show double-digit sales growth and by the similarly strong growth of Xyzal (levocetirizine) in the US and of Zyrtec (cetirizine) in Japan.